Pancreatic Enzyme Replacement Therapy: Background, Indications, and Pitfalls
DOI:
https://doi.org/10.69734/gqsbgc07Keywords:
Digestive Capacity, Exocrine Insufficiency, steatorrhea, pancreatic enzyme replacement, PERT, PEP, chronic pancreatitis, malabsorption, maldigestion, bloating, flatulence, diarrhea, SIBO, Bacterial Overgrowth, Failure to Thrive, Wasting, Pancreatic atrophy, Fatty pancreas, Pancreatic Cancer, Pancreatic surgery, Practical, Clinical, History of PERT or PEPAbstract
This review outlines the history, physiology, clinical circumstances, pharmacology, pitfalls and proper implementation of exogenous pancreatic enzyme replacement therapy (PERT).
Humanity has used PERT for hundreds of years--but in the last 30-50 years with much improved precision. Some topics that will be reviewed here include the complex diagnosis, prevalence, and long-term complications of Exocrine Pancreatic Insufficiency (EPI) and resultant dysfunction in Digestive Capacity (DC). The indications, efficacy, and safety of PERT in Exocrine Pancreatic Insufficiency (EPI). Optimizing PERT is not as easy as it seems. Many practical tips for PERT optimization are outlined for the reader.
References
DiMagno E. A short, eclectic history of exocrine pancreatic insufficiency and chronic pancreatitis. Gastroenterol. 1993;(104):1255-62. DOI: 10.1016/0016-5085(93)90332-7, PMID: 8482439.
Engesser H. Beitrage zur therapeutischen Verwendung der Bauchspeicheldruse von Schlachtthieren und deren Praparate. Dtsch Arch Klin Med. 1879;24:539-582.
Trang T, Chan J, Graham DY. Pancreatic enzyme replace-ment therapy for pancreatic exocrine insufficiency in the 21st century. World J Gastroenterol. 2014 Sep 7;20(33):11467-85. DOI: 10.3748/wjg.v20.i33.11467, PMCID: PMC4155341, PMID: 25206255.
Lieb II JG, Patel D, Karnik N, Toskes PP. Study of the gastro-intestinal bioavailability of a pancreatic extract product (Zenpep) in chronic pancreatitis patients with exocrine pancreatic insufficiency. Pancreatology. 2020 Sep;20(6):1092-102. Epub 2020 Aug 3. DOI: 10.1016/j.pan.2020.07.007, PMID: 32800653.
Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: prevalence, diagno-sis, and management. Clin Exp Gastroenterol. 2019 Mar 21;12:129-39. DOI: 10.2147/CEG.S168266, PMCID: PMC6432881, PMID: 30962702.
DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med. 1973 Apr 19;288(16):813-5. DOI: 10.1056/NEJM197304192881603, PMID: 4693931.
Wilcox CM, Rational Use of Fecal Elastase–1: Testing for Exocrine Pancreatic Insufficiency (EPI). SMART-MD Jour-nal of Precision Medicine 2024;1(2):15. DOI: 10.69734/hdhe8467.
Lieb II JG, Brensinger CM, Toskes PP. The significance of the volume of pancreatic juice measured at secretin stim-ulation testing: a single-center evaluation of 224 classical secretin stimulation tests. Pancreas. 2012 Oct;41(7):1073-9. DOI: 10.1097/MPA.0b013e318249a271, PMID: 22481285.
Domínguez–Muñoz EJ, Iglesias–García J, Vilariño–Insua M, Iglesias–Rey M. 13C-Mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastro and Hep. 2007 Apr;5(4):484-8. DOI: 10.1016/j.cgh.2007.01.004, PMID: 17445754.
Lieb II JG, Draganov PV. Pancreatic function testing: here to stay for the 21st century. World J Gastroenterol. 2008 May 28;14(20):3149-58. DOI: 10.3748/wjg.14.3149, PMCID: PMC2712845, PMID: 18506918.
Khan A, Vege SS, Dudeja V, Chari ST. Staging exocrine pancreatic dysfunction. Pancreatology 2021 Nov 19;22(1):168-72. DOI: 10.1016/j.pan.2021.11.005, PMID: 34916141.
Lankisch PG, Lembcke B, Wemken G, Creutzfeldt W. Func-tional reserve capacity of the exocrine pancreas. Diges-tion. 1986;35(3):175-81. DOI: 10.1159/000199364, PMID: 3781113.
Whitcomb DC, Duggan S, Martindale R, Lowe M, Stallings V, Conwell D, et al. AGA-PancreasFest joint symposium on exocrine pancreatic insufficiency. Gastro Hep Advances. 2023;2(3):395-411. DOI: 10.1016/j.gastha.2022.11.008.
Pham A, Forsmark CE. Chronic pancreatitis: review and update of etiology, risk factors, and management. F1000Res. 2018 May 17;7:607. [Version 1] DOI: 10.12688/f1000research.12852.1, PMCID: PMC5958317, PMID: 29946424.
Ramsey ML, Hart PA, Forsmark CE. Evaluation and man-agement of exocrine pancreatic insufficiency: pearls and pitfalls. Current Opinion in Gastroenterology. 2023 Sep;39(5):428-35. DOI: 10.1097/MOG.0000000000000951.
Frost F, Kacprowski T, Rühlemann M, Bülow R, Kühn JP, Franke A, et al. Impaired exocrine pancreatic function as-sociates with changes in intestinal microbiota composition and diversity. Gastroenterology. 2019 Mar;156(4):1010-5. DOI: 10.1053/j.gastro.2018.10.047, PMID: 30391469.
Forsmark CE, Tang G, Xu H, Tuft M, Hughes SJ, Yadav D. The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pan-creatic cancer in the US is infrequent and inconsistent. Al-iment Pharmacol Ther. 2020 May;51(10):958-67. Epub 2020 Apr 6. DOI: 10.1111/apt.15698, PMCID: PMC7299155, PMID: 32249970.
Ladna M, Madhok I, Bhat A, Ruiz N, Brown J, Wilson J, et al. Impact of order set on exocrine pancreatic insufficiency in chronic pancreatitis, pancreatic cancer, and pancreatic re-section. Gastro Hep Advances. Aug 30;4(1):100541. DOI: 10.1016/j.gastha.2024.08.019, PMID: 39790244.
Halloran CM, Cox TF, Chauhan S, Raraty MGT, Sutton R, Neoptolemos JP, Ghaneh P. Partial pancreatic resection for pancreatic malignancy is associated with sustained pan-creatic exocrine failure and reduced quality of life: a pro-spective study. Pancreatology. 2011;11(6):535-45. Epub 2011 Nov 15. DOI: 10.1159/000333308, PMID: 22094930.
Whitcomb DC, Lehman GA, Vasileva G, Malecka-Panas E, Gubergrits N, Shen Y, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. Am J Gastroenterol. 2010 Oct;105(10):2276-86. Epub 2010 May 25. DOI: 10.1038/ajg.2010.201, PMID: 20502447.
Toskes PP, Secci A, Thieroff-Ekerdt R, ZENPEP Study Group. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficien-cy due to chronic pancreatitis. Pancreas. 2011 Apr;40(3):376-82. DOI: 10.1097/MPA.0b013e31820b971c, PMID: 21343835.
Gan C, Chen Y, Liu L, Gao J, Tong H, Tang C, Liu R. Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a meta-analysis. Onco-target. 2017;8:94920-31. Retrieved from https://www.oncotarget.com/article/21659/text/.
Toskes. P. Clinical study report protocol no. VIO16EPI07-01: A multicenter, randomized, double-blind, parallel, pla-cebo-controlled, phase III study to assess the safety and efficacy of VIOKACE for the correction of steatorrhea. 5M01RR000082-47.
Lieb II JG, Curington C, Coston R, Dumoulin M, Shaw I, Toskes P. Delivery of enzymes into the duodenum of sub-jects with severe pancreatic exocrine insufficiency from a nonenteric coated enzyme preparation administered with omeprazole. Pancreas. 2009;38(8):1023.
Slaff J, Jacobson D, Tillman C, Curington CL, Toskes PP. Protease-specific suppression of pancreatic exocrine se-cretion. Gastroenterol. 1984;87(1). DOI:10.1016/0016-5085(84)90124-0, Corpus ID: 196309345.
Isaksson G, Ihse I. Pain reduction by an oral pancreatic enzyme preparation in chronic pancreatitis. Dig Dis Sci. 1983 Feb;28:97-102. DOI: 10.1007/BF01315137, PMID: 6825540.
Konstan MW, Stern RC, Trout JR, Sherman JM, Eigen H, Wagener JS, et al. Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fi-brosis: safety and efficacy. Aliment Pharmacol Ther. 2004;20:1365–71. DOI: 10.1111/j.1365-2036.2004.02261.x, PMID: 15606399.
Gardner TB, Adler DG, Forsmark CE, Sauer RG, Taylor JR, Whitcomb DC. ACG clinical guideline: chronic pancreatitis. Am J Gastroenterol. 2020 Mar;115(3):322-39. DOI: 10.14309/ajg.0000000000000535, PMID: 32022720.
Chonchubhair HM, Bashir Y, Dobson M, Ryan BM, Duggan SN, Conlon KC. The prevalence of small intestinal bacterial overgrowth in non-surgical patients. Pancreatology. 2018 Jun;18(4):379-85. DOI: 10.1016/j.pan.2018.02.010, PMID: 29502987.
Piciucchi M, Capurso G, Archibugi L, Delle Fave MM, Ca-passo M, Delle Fave G. Exocrine pancreatic insufficiency in diabetic patients: prevalence, mechanisms, and treat-ment. Int J Endocrinol. 2015 Mar 29;2015:595649. DOI: 10.1155/2015/595649.
Andersen DK, Murray Korc M, Petersen GM, Eibl G, Li D, Rickels MR, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes. 2017 May;66(5):1103-10. DOI: 10.2337/db16-1477, PMCID: PMC5399609, PMID: 28507210.
Forsmark CE. Management of chronic pancreati-tis. Gastroenterology. 2013;144(6):1282–91.e3. DOI: 10.1053/j.gastro.2013.02.008, PMID: 23622138.
Whitcomb DC, Buchner AM, Forsmark CE. AGA clinical practice update on the epidemiology, evaluation, and management of exocrine pancreatic insufficiency: expert review. Gastroenterology. 2023;165(5):1292-301. DOI: 10.1053/j.gastro.2023.07.007, PMID: 37737818.
Stevens J, Wyatt C, Brown P, Patel D, Grujic D, Freedman SD. Absorption and safety with sustained use of RELiZORB evaluation (ASSURE) study in patients with cystic fibrosis receiving enteral feeding. J Pediatr Gastroenterol Nutr. 2018 Oct;67(4):527-32. DOI: 10.1097/MPG.0000000000002110, PMCID: PMC6155360, PMID: 30074573.
Ng C, Major G, Smyth AR. Dosing regimens for pancreatic enzyme replacement therapy (PERT) in cystic fibrosis. Cochrane Database Syst Rev. 2019 Dec 19;2019(12):CD013488. DOI: 10.1002/14651858.CD013488.
Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Figueiras A, Vilarino-Insua M. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic en-zyme supplements in patients with exocrine pancreatic in-sufficiency: a randomized, three-way crossover study. Al-iment Pharmacal Ther. 2005;21(8):993–1000. DOI: 10.1111/j.1365-2036.2005.02390.x, PMID: 15813835.
Ketwaroo GA, Graham DY. Rational use of pancreatic enzymes for pancreatic insufficiency and pancreatic pain. Adv Exp Med Biol. 2019:1148:323-43. DOI: 10.1007/978-981-13-7709-9_14, PMCID: PMC6913179, PMID: 31482505.
Graham DY, Sackman JW. Mechanism of increase in steatorrhea with calcium and magnesium in exocrine pan-creatic insufficiency: an animal model. Gastroenterol. 1982;83(3):638-44. PMID: 7095367.
Shah ND, Limketkai BN. The use of medium chain triglycer-ides in gastrointestinal disorders. Practical Gastroenterol-ogy, 2017 Feb;41(2):20-8.
Kuan LL, Ashley R, Dennison AR, Garcea G. Prevalence and impact of sarcopenia in chronic pancreatitis: A review of the literature. World J Surg. 2020 Nov 9;45(2):590–7. DOI: 10.1007/s00268-020-05828-0, PMCID: PMC7773619, PMID: 33165641.
Wagle D, Regmi D, Regmi S. A case of exocrine insufficien-cy in a gastric bypass patient. J Surg Med. 2024;8(11): 185-7. DOI: https://DOI.org/10.28982/josam.7897.
Simpson KW, Batt RM, Jones D, Morton DB. Effects of exocrine pancreatic insufficiency and replacement therapy on the bacterial flora of the duodenum in dogs. Am J Vet Res. 1990 Feb;51(2):203-6. PMID: 2301831.
Zhang J, Hou J, Liu D, Lv Y, Zhang C, Su X, et al. The preva-lence and characteristics of exocrine pancreatic insuffi-ciency in patients with type 2 Diabetes: A systematic re-view and meta-analysis. Int J Endocrinol. 2022;2022:7764963 DOI: 10.1155/2022/7764963, PMID: 36213198.
Downloads
Published
Versions
- 2025-05-21 (2)
- 2025-03-31 (1)
Issue
Section
License
Copyright (c) 2025 SMART-MD Journal of Precision Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal information